Back to top
more

Avid Bioservices (CDMO)

(Real Time Quote from BATS)

$10.40 USD

10.40
199,828

+0.13 (1.27%)

Updated Nov 4, 2024 03:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of -16.67% and 83.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings Beat Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of 450% and 1.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0% and 26.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Avid Bioservices (CDMO) closed at $20.24 in the latest trading session, marking a -0.3% move from the prior day.

Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avid (CDMO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.

    Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.

    Avid Bioservices (CDMO) Stock Moves -1.6%: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Avid Bioservices (CDMO) closed at $21.54, marking a -1.6% move from the previous day.

    Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.

    Avid Bioservices (CDMO) Stock Moves -1.67%: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Avid Bioservices (CDMO) closed at $18.20, marking a -1.67% move from the previous day.

    Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices

    by Zacks Equity Research

    Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices

    Bryan Hayes headshot

    Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength

    by Bryan Hayes

    3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

    Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.

    Avid Bioservices (CDMO) Loses 24.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    by Zacks Equity Research

    The heavy selling pressure might have exhausted for Avid Bioservices (CDMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Avid Bioservices (CDMO) Tops Q2 Earnings and Revenue Estimates

    by Zacks Equity Research

    Avid Bioservices (CDMO) delivered earnings and revenue surprises of 400% and 4.44%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

    The Cooper Companies (COO) Q4 Earnings Lag Estimates

    by Zacks Equity Research

    The Cooper Companies (COO) delivered earnings and revenue surprises of -2.67% and 1.52%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

    Avid Bioservices (CDMO) Earnings Expected to Grow: What to Know Ahead of Q2 Release

    by Zacks Equity Research

    Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022

    by Zacks Equity Research

    Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.

    Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

    by Zacks Equity Research

    Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

    Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?

    by Zacks Equity Research

    Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?

    by Zacks Equity Research

    Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis

    by Zacks Equity Research

    Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.